LDS/Medical Tests/Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue

Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue

Endometrial stromal tumors (ESTs) are a rare and heterogeneous group of mesenchymal neoplasms that arise from endometrial stromal cells of the uterus. According to the World Health Organization (WHO) 2020 classification, ESTs are divided into four main categories: endometrial stromal nodule (a benign neoplasm), low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS). These tumors are uncommon, with an estimated incidence of approximately 0.3 per 100,000 women per year, and most frequently occur in peri-menopausal or post-menopausal patients.

Molecular characterization has become essential for accurate diagnosis and classification of ESTs. LG-ESS is most commonly associated with gene fusions involving JAZF1 at chromosome 7p15, frequently with SUZ12 or other fusion partners, as well as rearrangements involving PHF1 at 6p21.32. These tumors typically show indolent behavior and often retain expression of estrogen and progesterone receptors. In contrast, a subset of tumors previously classified as high-grade or undifferentiated has been shown to harbor YWHAE rearrangements at 17p13.3, most commonly YWHAE–NUTM2 fusions, which define a biologically aggressive subtype now classified as high-grade endometrial stromal sarcoma. These tumors often lack hormone receptor expression and demonstrate high-grade morphology.

Undifferentiated uterine sarcoma generally lacks recurrent, defining gene rearrangements and represents a diagnosis of exclusion, characterized by marked nuclear atypia, high mitotic activity, and aggressive clinical behavior. Because ESTs can closely mimic other uterine mesenchymal tumors, including leiomyosarcoma, carcinosarcoma, and high-grade endometrial carcinoma, integration of morphologic assessment, immunohistochemistry, and molecular testing is critical for accurate diagnosis. Identification of specific gene rearrangements by fluorescence in situ hybridization (FISH) provides objective molecular evidence that supports tumor classification, informs prognosis, and may influence therapeutic decisions.

  •           Confirms and subtypes endometrial stromal tumors by identifying characteristic gene rearrangements
  • Distinguishes low-grade endometrial stromal sarcoma from high-grade endometrial stromal sarcoma and other uterine mesenchymal tumors
  • Supports prognostic assessment by identifying molecular features associated with aggressive clinical behavior
  • Assists in resolving diagnostically equivocal cases when histology and immunohistochemistry are inconclusive

A positive result is defined by detection of a rearrangement involving JAZF1, PHF1, or YWHAE above the established laboratory cutoff. Identification of JAZF1 or PHF1 rearrangements supports a diagnosis of low-grade endometrial stromal sarcoma in the appropriate morphologic context. Detection of YWHAE rearrangement is strongly associated with high-grade endometrial stromal sarcoma and indicates a more aggressive clinical course.

A negative result indicates that the targeted rearrangements were not detected. This finding does not exclude the presence of an endometrial stromal tumor, as not all cases harbor detectable genetic abnormalities and technical factors such as low tumor cellularity or probe limitations may affect sensitivity. Results should always be interpreted in conjunction with histopathology, immunohistochemical findings, and clinical information.

Targeted genetic rearrangements (JAZF1, PHF1, YWHAE): Not detected

Fluorescent in situ hybridization (FISH) using dual-color, break-apart probes for JAZF1, PHF1, and YWHAE.

 

Tissue, Formalin-fixed paraffin embedded (FFPE), extracted from tumor-rich area.

FFPE specimens are stable at ambient for longer time.

Endometrial biopsy, hCG, CA125, CBC, PTEN gene mutation analysis, HPV DNA PCR, PAP smear.

7 to 10 days.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login